Download PDF

1. Company Snapshot

1.a. Company Description

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products.The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes.It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name.


In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name.It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China.LifeVantage Corporation is headquartered in Lehi, Utah.

Show Full description

1.b. Last Insights on LFVN

LifeVantage Corporation's recent performance was negatively impacted by disappointing Q4/FY2025 results, with domestic sales of the MindBody GLP-1 System coming in below expectations. The company's FY2026 guidance was also below consensus expectations, with organic growth near zero at the mid-point of the provided revenue range. Additionally, the MindBody GLP-1 System sales have largely failed to keep pace with blockbuster weight-loss drugs. A downgrade was issued by an analyst due to these results.

1.c. Company Highlights

2. LifeVantage's Q1 2026 Earnings: A Strategic Shift in Wellness

LifeVantage reported net revenue of $47.6 million for Q1 2026, a modest 0.7% increase from $47.2 million in the prior year period. Gross margin stood at 79.5%, down 40 basis points from the previous year. Adjusted non-GAAP net income was $2.3 million, or $0.18 per fully diluted share, beating estimates of $0.17 per share. Adjusted EBITDA of $3.9 million was down $500,000 versus last year due to lower contribution margin, partially offset by lower SG&A.

Publication Date: Nov -21

📋 Highlights
  • Strategic Acquisition Completed:: Acquisition of LoveBiome finalized, positioning in the gut microbiome market projected to grow from $14.4B in 2025 to $32.4B by 2035.
  • Q1 2026 Revenue Growth:: Net revenue rose 0.7% to $47.6M, with adjusted EBITDA at $3.9M (8.2% of revenue), down $500K YoY.
  • Integration Progress:: LoveBiome systems fully integrated; consultant cross-selling training initiated, enhancing a combined community of passionate entrepreneurs.
  • Strong Financial Position:: $13.1M cash on hand, $5M credit line, and $600K share buybacks at $13/share during Q1.
  • Product Innovation:: P84 in vitro studies show it boosts 14 gut-health peptides; gut health market growth forecasted to $35B over 10 years.

Strategic Acquisition and Integration

The acquisition of LoveBiome represents a significant shift in LifeVantage's business, positioning it within the rapidly growing gut microbiome health market. The integration is largely complete, with positive early indicators from the consultant community integration. The company is seeing opportunities for cross-selling and has begun training its consultants. As Douglas Lane mentioned, combining LifeVantage's P84 with LoveBiome's products could create a compelling offering, particularly in the gut health segment.

Growth Prospects and Guidance

LifeVantage remains optimistic about its growth trajectory, with the successful integration of LoveBiome expected to drive future revenue. The company continues to expect full-year revenue in the range of $225 million to $240 million and adjusted non-GAAP EBITDA in the range of $23 million to $26 million. Analysts estimate next year's revenue growth at -1.2%, indicating a potential slowdown. However, the company's diversified product offerings and expanding presence in the wellness market could help mitigate this.

Valuation and Dividend

LifeVantage's current valuation metrics, including a P/E Ratio of 7.72 and a Dividend Yield of 2.69%, suggest a relatively attractive profile. The company's strong financial position, with $13.1 million in cash and no debt, supports its dividend payments and share repurchases. The announced quarterly cash dividend of $0.045 per share will be paid on December 15, 2025, to stockholders of record as of December 1, 2025.

ROIC and ROE

LifeVantage's ROIC stands at 23.07%, and ROE at 30.78%, indicating a strong ability to generate returns on invested capital and equity. These metrics suggest that the company is efficiently utilizing its resources to drive profitability.

3. NewsRoom

Card image cap

Head to Head Review: Pro-Dex (NASDAQ:PDEX) vs. Lifevantage (NASDAQ:LFVN)

Nov -18

Card image cap

New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

Nov -12

Card image cap

Lifevantage (LFVN) Q1 Earnings Top Estimates

Nov -05

Card image cap

LifeVantage Corporation (LFVN) Q1 2026 Earnings Call Transcript

Nov -04

Card image cap

LifeVantage Declares Quarterly Dividend

Nov -04

Card image cap

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

Nov -04

Card image cap

LifeVantage Empowers Consultants to “Love Life & Drive” at Momentum Academy 2025

Oct -28

Card image cap

LifeVantage to Announce First Quarter Fiscal Year 2026 Results on November 4, 2025

Oct -21

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (1.05%)

6. Segments

Protandim

Expected Growth: 1.2%

Protandim's 1.2 growth driven by increasing demand for anti-aging and wellness products, expanding distribution channels, and strong online presence. Additionally, the product's unique Nrf2-activating properties and scientific backing contribute to its popularity, while LifeVantage's strategic partnerships and loyalty programs foster customer retention and acquisition.

TrueScience

Expected Growth: 0.8%

TrueScience's 0.8 growth driven by increasing demand for anti-aging skincare, expanding online presence, and strategic partnerships. Strong brand recognition, proprietary blend of Nrf2-activating ingredients, and scientifically-backed products contribute to customer loyalty and retention. Effective marketing strategies, including influencer partnerships and social media campaigns, also fuel growth.

Other

Expected Growth: 0.9%

LifeVantage Corporation's 0.9 growth in 'Other' segment is driven by increasing demand for its nutrigenomic products, expansion into new markets, and strategic partnerships. Additionally, the company's focus on e-commerce and digital marketing has improved customer engagement, leading to higher sales. Furthermore, the company's efforts to reduce costs and improve operational efficiency have contributed to the growth.

7. Detailed Products

Protandim Nrf2

A dietary supplement that activates the Nrf2 pathway, which helps to reduce oxidative stress and inflammation in the body.

Protandim NRF1

A dietary supplement that targets the NRF1 pathway, which helps to promote mitochondrial function and energy production.

Protandim NAD

A dietary supplement that targets the NAD+ pathway, which helps to promote cellular energy production and reduce oxidative stress.

TrueScience

A line of skincare products that utilize the power of Nrf2 to promote healthy skin and reduce the signs of aging.

Petandim

A dietary supplement designed for pets, which helps to reduce oxidative stress and inflammation in pets.

AXIO

A line of energy drinks and supplements that provide a natural energy boost and support overall health and wellness.

8. LifeVantage Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for LifeVantage Corporation is moderate due to the presence of alternative health and wellness products in the market.

Bargaining Power Of Customers

The bargaining power of customers is low due to the company's strong brand reputation and customer loyalty.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the company's dependence on a few key suppliers for raw materials.

Threat Of New Entrants

The threat of new entrants is high due to the low barriers to entry in the health and wellness industry.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the health and wellness industry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 27.42%
Debt Cost 3.95%
Equity Weight 72.58%
Equity Cost 8.07%
WACC 6.94%
Leverage 37.77%

11. Quality Control: LifeVantage Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Seneca Foods

A-Score: 6.1/10

Value: 7.1

Growth: 7.2

Quality: 4.4

Yield: 0.0

Momentum: 10.0

Volatility: 7.7

1-Year Total Return ->

Stock-Card
John B. Sanfilippo & Son

A-Score: 5.2/10

Value: 7.3

Growth: 4.4

Quality: 6.1

Yield: 6.0

Momentum: 0.5

Volatility: 7.0

1-Year Total Return ->

Stock-Card
Nature's Sunshine Products

A-Score: 5.0/10

Value: 6.5

Growth: 4.1

Quality: 6.5

Yield: 1.0

Momentum: 7.0

Volatility: 5.0

1-Year Total Return ->

Stock-Card
LifeVantage

A-Score: 4.6/10

Value: 7.0

Growth: 4.6

Quality: 7.3

Yield: 5.0

Momentum: 1.0

Volatility: 2.7

1-Year Total Return ->

Stock-Card
Mama's Creations

A-Score: 4.6/10

Value: 0.6

Growth: 8.8

Quality: 5.9

Yield: 0.0

Momentum: 8.5

Volatility: 3.7

1-Year Total Return ->

Stock-Card
Lifeway Foods

A-Score: 4.2/10

Value: 2.2

Growth: 8.2

Quality: 6.2

Yield: 0.0

Momentum: 5.0

Volatility: 3.3

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.6$

Current Price

6.6$

Potential

-0.00%

Expected Cash-Flows